Fierce Pharma March 26, 2024
Angus Liu

The CEOs of AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, Pfizer and Takeda came together in Beijing to show the companies’ continued interest in China and to offer their advice for the country’s healthcare industry.

Pfizer CEO Albert Bourla, while complimenting China’s large market opportunity, urged the Chinese government to further improve its protection of intellectual property, according to a Pfizer social media post (Chinese).

Bourla made the comment Sunday during a one-on-one dialogue with Li Daokui, an economist at Tsinghua University who is known as a key adviser to China’s core leadership, at the annual China Development Forum (CDF). Back in 2019, Li had stated that Beijing could block exports of medicines as a countermeasure to the U.S.’s trade...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
AstraZeneca withdraws COVID-19 vaccine, citing declining demand
Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test
Drug patents protect pharma profits. Track when they’ll expire here.
Cell therapy fails to slow early type 1 diabetes, but safety is established
How Peter Marks plans to prevent '3 billion visits' to FDA

Share This Article